Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
MOMENTUM-1
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
- NCT06955169 ↗
- Recruiting
- RTOG Foundation, Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Intracranial Meningioma
- Interventions
- [177Lu]Lu-DOTATATE; Standard of Care treatments
- Arms
- [177Lu]Lu-DOTATATE · Experimental
- Control · Other
- Enrollment
- 130 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- RTOG Foundation, Inc. with Novartis Pharmaceuticals
- Start
- Aug 24, 2025
- Primary completion
- Aug 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06955169 · updated Oct 2, 2026